Cargando…

Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA

INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is the classic progressive fibrosing interstitial lung disease (ILD), but some patients with ILDs other than IPF also develop a progressive fibrosing phenotype (PF-ILD). Information on use and cost of healthcare resources in patients with PF-ILD is l...

Descripción completa

Detalles Bibliográficos
Autores principales: Olson, Amy L., Maher, Toby M., Acciai, Valentina, Mounir, Baher, Quaresma, Manuel, Zouad-Lejour, Leila, Wells, Christopher D., De Loureiro, Lou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467408/
https://www.ncbi.nlm.nih.gov/pubmed/32451950
http://dx.doi.org/10.1007/s12325-020-01380-4
_version_ 1783578006732668928
author Olson, Amy L.
Maher, Toby M.
Acciai, Valentina
Mounir, Baher
Quaresma, Manuel
Zouad-Lejour, Leila
Wells, Christopher D.
De Loureiro, Lou
author_facet Olson, Amy L.
Maher, Toby M.
Acciai, Valentina
Mounir, Baher
Quaresma, Manuel
Zouad-Lejour, Leila
Wells, Christopher D.
De Loureiro, Lou
author_sort Olson, Amy L.
collection PubMed
description INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is the classic progressive fibrosing interstitial lung disease (ILD), but some patients with ILDs other than IPF also develop a progressive fibrosing phenotype (PF-ILD). Information on use and cost of healthcare resources in patients with PF-ILD is limited. METHODS: We used USA-based medical insurance claims (2014–2016) to assess use and cost of healthcare resources in PF-ILD. Patients with at least two ILD claims and at least one pulmonologist visit were considered to have ILD. Pulmonologist visit frequency was used as a proxy to identify PF-ILD (at least four visits in 2016, or at least three more visits in 2016 vs. 2014). RESULTS: Of 2517 patients with non-IPF ILD, 15% (n = 373) had PF-ILD. Mean annual medical costs associated with ILD claims were $35,364 in patients with non-IPF PF-ILD versus $20,211 in the non-IPF ILD population. In 2016, patients with non-IPF PF-ILD made more hospital ILD claims than patients with non-IPF ILD (10.5 vs. 4.7). CONCLUSIONS: These findings suggest higher disease severity and overall healthcare use for patients with a non-IPF ILD manifesting a progressive fibrosing phenotype (non-IPF PF-ILD). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12325-020-01380-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7467408
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-74674082020-09-11 Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA Olson, Amy L. Maher, Toby M. Acciai, Valentina Mounir, Baher Quaresma, Manuel Zouad-Lejour, Leila Wells, Christopher D. De Loureiro, Lou Adv Ther Original Research INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is the classic progressive fibrosing interstitial lung disease (ILD), but some patients with ILDs other than IPF also develop a progressive fibrosing phenotype (PF-ILD). Information on use and cost of healthcare resources in patients with PF-ILD is limited. METHODS: We used USA-based medical insurance claims (2014–2016) to assess use and cost of healthcare resources in PF-ILD. Patients with at least two ILD claims and at least one pulmonologist visit were considered to have ILD. Pulmonologist visit frequency was used as a proxy to identify PF-ILD (at least four visits in 2016, or at least three more visits in 2016 vs. 2014). RESULTS: Of 2517 patients with non-IPF ILD, 15% (n = 373) had PF-ILD. Mean annual medical costs associated with ILD claims were $35,364 in patients with non-IPF PF-ILD versus $20,211 in the non-IPF ILD population. In 2016, patients with non-IPF PF-ILD made more hospital ILD claims than patients with non-IPF ILD (10.5 vs. 4.7). CONCLUSIONS: These findings suggest higher disease severity and overall healthcare use for patients with a non-IPF ILD manifesting a progressive fibrosing phenotype (non-IPF PF-ILD). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12325-020-01380-4) contains supplementary material, which is available to authorized users. Springer Healthcare 2020-05-21 2020 /pmc/articles/PMC7467408/ /pubmed/32451950 http://dx.doi.org/10.1007/s12325-020-01380-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Olson, Amy L.
Maher, Toby M.
Acciai, Valentina
Mounir, Baher
Quaresma, Manuel
Zouad-Lejour, Leila
Wells, Christopher D.
De Loureiro, Lou
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
title Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
title_full Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
title_fullStr Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
title_full_unstemmed Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
title_short Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
title_sort healthcare resources utilization and costs of patients with non-ipf progressive fibrosing interstitial lung disease based on insurance claims in the usa
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467408/
https://www.ncbi.nlm.nih.gov/pubmed/32451950
http://dx.doi.org/10.1007/s12325-020-01380-4
work_keys_str_mv AT olsonamyl healthcareresourcesutilizationandcostsofpatientswithnonipfprogressivefibrosinginterstitiallungdiseasebasedoninsuranceclaimsintheusa
AT mahertobym healthcareresourcesutilizationandcostsofpatientswithnonipfprogressivefibrosinginterstitiallungdiseasebasedoninsuranceclaimsintheusa
AT acciaivalentina healthcareresourcesutilizationandcostsofpatientswithnonipfprogressivefibrosinginterstitiallungdiseasebasedoninsuranceclaimsintheusa
AT mounirbaher healthcareresourcesutilizationandcostsofpatientswithnonipfprogressivefibrosinginterstitiallungdiseasebasedoninsuranceclaimsintheusa
AT quaresmamanuel healthcareresourcesutilizationandcostsofpatientswithnonipfprogressivefibrosinginterstitiallungdiseasebasedoninsuranceclaimsintheusa
AT zouadlejourleila healthcareresourcesutilizationandcostsofpatientswithnonipfprogressivefibrosinginterstitiallungdiseasebasedoninsuranceclaimsintheusa
AT wellschristopherd healthcareresourcesutilizationandcostsofpatientswithnonipfprogressivefibrosinginterstitiallungdiseasebasedoninsuranceclaimsintheusa
AT deloureirolou healthcareresourcesutilizationandcostsofpatientswithnonipfprogressivefibrosinginterstitiallungdiseasebasedoninsuranceclaimsintheusa